FINWIRES · TerminalLIVE
FINWIRES

Top Midday Stories: GE Vernova Shares Gain on Strong Q1 Earnings, Guidance; Vertiv Lifts Guidance After Q1 EPS, Revenue Beats, Shares Fall

-- All three major US stock indexes were up in late-morning trading Wednesday following reports of Iranian attacks on vessels in the Strait of Hormuz and President Donald Trump's extension of the ceasefire between the warring nations.

In company news, GE Vernova (GEV) reported Q1 earnings Wednesday of $17.44 per share, up from $0.91 a year earlier. Total Q1 revenue was $9.34 billion, up from $8.03 billion a year ago and above the FactSet consensus analyst estimate of $9.25 billion. For 2026, the company said it expects revenue of about $44.5 billion to $45.5 billion, up from its previous outlook of $44 billion to $45 billion and compared to the FactSet consensus of $44.66 billion. GE Vernova shares were up 12.4% around midday.

Vertiv (VRT) reported Q1 adjusted earnings Wednesday of $1.17 per diluted share, up from $0.64 a year earlier and above the FactSet consensus of $1.00. First-quarter revenue was $2.65 billion, up from $2.04 billion a year ago and above the FactSet consensus of $2.64 billion. For Q2, the company said it expects adjusted EPS of $1.37 to $1.43 on revenue of $3.25 billion to $3.45 billion. Analysts polled by FactSet expect $1.43 and $3.40 billion, respectively. For full-year 2026, Vertiv said it expects adjusted EPS of $6.30 to $6.40, up from its previous outlook of $5.97 to $6.07 and above the FactSet consensus of $6.12. Vertiv expects full-year revenue to be $13.50 billion to $14.00 billion, up from its previous guidance of $13.25 billion to $13.75 billion and compared to the FactSet consensus of $13.63 billion. Vertiv shares were down 2.6%.

Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical have expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that could be valued at over $8 billion, Reuters reported Wednesday, citing people familiar with the matter. Merck shares were down 0.2%, while Inhibrx shares were up 31.9%.

Boeing (BA) reported a Q1 core loss Wednesday of $0.20 per share, narrowing from a loss of $0.49 a year earlier and compared to the FactSet consensus estimate of a loss of $0.68. First-quarter revenue was $22.22 billion, up from $19.50 billion a year ago and above the FactSet consensus of $21.85 billion. Cash outflow for the quarter was $1.45 billion, narrowing from $2.29 billion a year ago, and the company said Q1 deliveries increased 10% to 143 planes. Boeing shares were up 5.4%.

Alphabet's (GOOG, GOOGL) Google Cloud is launching a $750 million fund to help consulting firms like Accenture (ACN), McKinsey and Deloitte get their clients to use agentic AI software, Bloomberg reported Wednesday, citing an emailed statement and an interview with a company official. Alphabet's Class C and Class A shares were up 1.5% and 1.6%, respectively. Accenture shares were down 1.9%.

Philip Morris International (PM) reported Q1 adjusted earnings Wednesday of $1.96 per diluted share, up from $1.69 a year earlier and above the FactSet consensus of $1.83. Net Q1 revenue was $10.15 billion, up from $9.30 billion ay ear ago and above the FactSet consensus of $9.91 billion. For Q2, Philip Morris said it expects adjusted EPS of $2.02 to $2.07, below the FactSet consensus of $2.12. For full-year 2026, the company said it expects adjusted EPS of $8.36 to $8.51, compared to the FactSet consensus of $8.38. Philip Morris shares were up 7%.

Boston Scientific (BSX) reported Q1 adjusted earnings Wednesday of $0.80 per share, up from $0.75 a year earlier and above the FactSet consensus of $0.79. First-quarter net sales were $5.20 billion, up from $4.66 billion a year ago and above the FactSet consensus of $5.17 billion. For Q2, Boston Scientific said it expects adjusted EPS of $0.82 to $0.84 and net sales growth of 5.5% to 7.5%. Analysts polled by FactSet expect adjusted EPS of $0.86. For full-year 2026, the company said it expects adjusted EPS of $3.34 to $3.41, down from its prior outlook of $3.43 to $3.49 and below the FactSet consensus of $3.45. Full-year net sales are now expected to grow about 7.0% to 8.5%, down from the company's previous guidance of 10.5% to 11.5% growth. Shares of the company were up 8.4%.

AT&T (T) reported Q1 earnings Wednesday of $0.54 per diluted share, down from $0.61 a year earlier and below the FactSet consensus of $0.55. First-quarter operating revenue was $31.51 billion, up from $30.63 billion a year ago and above the FactSet consensus of $31.25 billion. AT&T shares were down 1.8%.

Price: $1119.35, Change: $+128.05, Percent Change: +12.92%

相關文章

Asia

Metaplanet發行債券後削減比特幣融資計劃

根據東京證券交易所週五發布的公告顯示,Metaplanet(東京證券交易所代碼:3350)正在調整其資金用途,將80億日元用於債券贖回,同時減少原計劃的比特幣購買量。 這項調整源自於該公司發行了80億日圓債券,最初計劃用於購買比特幣的資金,現在部分用於償還債券,因為股票認購權正在行使。 該公司將原計劃的比特幣購買量從334.2億日圓削減至254.2億日元,同時保留37.1億日圓用於比特幣收益。

$TYO:3350
Asia

韓華將在內部重組中吸收旗下HKG Trading部門

根據週五在東京證券交易所發布的公告,韓和集團(TYO:8078)將與其全資子公司HKG Trading進行吸收式分拆,以精簡營運並加強集團管理。 此次分拆將把集團旗下部分公司的資產、負債和業務職能轉移至韓和集團,重組將於6月30日生效。 此次分拆不涉及現金對價,韓和集團的資本將維持不變。

$TYO:8078
Asia

Tomen Devices 中期計畫(至 2028 年)設定 130 億日圓利潤目標

根據東京證券交易所週五發布的公告,Tomen Devices(TYO:2737)在其截至2028財年的中期計劃中,將以人工智慧相關業務增長和全球擴張為驅動力,實現淨利潤130億日元和15%的股本回報率。 該公司計劃利用其核心記憶體業務以及與三星的合作關係,拓展人工智慧解決方案,尤其是在推理領域,同時擴大在汽車和伺服器/儲存領域的業務規模。 Tomen Devices的目標是加強海外成長,重點關注亞洲和北美市場,同時投資高達150億日圓用於擴張,並維持穩定的財務基礎。 該公司還設定了每股最低300日圓的股息,並計劃在最後一個財年實現40%的派息率,預計在計劃期內將產生約600億日元的經營現金流。

$TYO:2737